ESMO 2022 | Potential of CTCs for biomarker detection in prostate cancer

Andrew Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, explores the role of circulating tumor cells (CTCs) in the identification of biomarkers that will predict response to PSMA-targeted therapies. Dr Armstrong discusses the PROPHECY study (NCT02269982) which aimed to validate AR-V7 as a predictive biomarker for the treatment of men with metastatic castration-resistant prostate cancer with abiraterone acetate. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.